Few ideas in medicine have caught on so fast or been as successful as postgraduate medical centres. The Christ Church conference in 1961 started what was soon to become an explosion of activity; generous grants from the Nuffield Provincial Hospitals Trust and the King's Fund enabled the initial plans to achieve reality; local enthusiasm and fund raising subsequently got centres built and running; and the selfless energy of postgraduate tutors built up vigorous educational programmes suited to individual needs. Today there are probably some 300 centres in Britain, playing an important part in programmes of vocational and continuing education.
It is necessary to rehearse all these facts because they illustrate one fundamental principle of postgraduate centres: they were built by doctors for doctors. Certainly some centres have established excellent relationships and cooneration with members of the dental and paramedical profec-sions, but the fact remains that they are primarily intended for doctors, and their control must remain in the bands of the postgraduate tutors who set them up. This has been recognized by the Scottish Home and Health Department, which is emphatic that centres should cater for doctors only. To the tidy bureaucratic mind the average postgraduate centre must apDear as an underused canital-intens;ve structure. What better wnv of achieving an ontimum return than to ensure its being full for 12 hours a day? Yet a mere look at the statistics-or a visit to an actual centre-should convince anyone that this impression is wrong. A survey of three centres in the North-west Metropolitan Region showed regular clinicopathological and lunch-time meetings, medical films, and evening classes at one of them; 10 meetings held every week at a second; and Sunday morning symposia for hospital junior staff or general practitioners, refresher courses and symposia, a lunch-club meeting, and a History of Medicine series-as well as career talks for local schoolchildren-at a third. And a visit to the average centre will show doctors working in the library, listening to audiotapes, or looking at colour transparencies, or merely talking to colleagues in different disciplines about a clinical problem.
It might have been thought that these problems could have been solved by patience and good will, but on present experience this does not seem likely. Surely it is better to agree now that the educational interests of doctors and the other professions are totally different and can never coincide. The established pattern of the postgraduate medical centre, which has already achieved so much, should be allowed to remain as it is.
Confusion with Clofibrate
The recent findings of the Scottish and Newcastle Physicians,' 2 reporting double-blind trials of clofibrate on 1,214 patients with ischaemic heart disease, have been widely publicized and greeted with both acclaim and sober criticism.3 In both trials the mortality fell in patients with angina who were treated with clofibrate, whether or not they had had a previous myocardial infarct. The reduction in the total of fatal and non-fatal infarctions was also significant in thece "angina" patients. But, when non-fatal infarctions are considered alone, no significant reduction had occurred. A protective effect in the Newcastle patients with previous infarction can possibly be attributed to the fact that the majority of these patients had also had angina. presence or absence of angina should influence the usefulness of clofibrate, and, as seems possible from the Newcastle study, it is surprising to find that the benefit from clofibrate might not be related to its lipid-lowering action.
L. R. Krasno and G. J. Kidera, from San Francisco, have now reported their findings5 in 1,068 men, of whom 67 had ischaemic heart disease, followed up for 62 months. The patients were randomly allocated according to age, blood pressure, weight, smoking habits, lipid levels, and incidence of heart disease. Five hundred and eighteen received clofibrate throughout the study. The other 550 were untreated for 39 months and then received clofibrate for the final 23 months. In the first period the infarction rate fell in clofibrate-treated patients, with and without previous heart disease. The patients treated only in the second period showed a significant reduction in incidence of infarction in that period. In this study clofibrate had no influence on mortality. Cholesterol and triglyceride levels were measured, and 62% and 70% of treated patients with abnormal levels had a worthwhile reduction. Hyperlipidaemia was an important factor in this study: 18 of 19 patients (14 untreated) developing infarction in the first 39 months had a hyperlipidaemia. But no correlation was found between lipidlowering effects and benefit from clofibrate; no infarction occurred in hyperlipidaemic subjects not responding to clofibrate. It is not clear if the benefit from clofibrate is still significant when these non-responders are excluded from consideration. This trial was not double-blind and is open to criticism on the grounds that the treated patients may have become more "coronary conscious" and taken other protective measures. Krasno and Kidera have also made an interim report of a continuing primary prevention study in young males without heart disease. When 1,049 patients left untreated for 23 months are compared with 1,169 patients treated with clofibrate for 32 months a significant difference in the incidence of coronary artery disease is already evident. Further results from this study will be interesting; so too will be the reports from the large doubleblind primary prevention trial at present proceeding in Edinburgh and Budapest.
These studies have not defined the place of clofibrate in clinical practice. Indeed they have cast some doubt on the generally accepted theory that the drug acts by reducing the levels of cholesterol and triglycerides. But it would be premature to dismiss this explanation on the present inconclusive evidence. Clofibrate does lower serum cholesterol and triglyceride levels in most patients, and a reduction in hepatic lipid content has been demonstrated.6 A blqck occurs in cholesterol biosynthesis at a stage between acetate and mevalonate, so that precursors prior to the site of the block are readily metabolized, and potentially atherogenic precursors do not accumulate.7 Though increased faecal excretion of cholesterol and its metabolites has been suggested as a further mode of action of clofibrate,8 recent studies have shown decreased faecal excretion of bile acid, probably reflecting reduced hepatic synthesis and catabolism of cholesterol.9 The effect on triglyceride may be a result of the occupation by clofibrate, being strongly protein-bound, of binding sites used for the transport of non-esterified fatty acids, thus reducing their supply to the liver, with a resultant fall in triglyceride synthesis.'0 But there are other possible mechanisms of action. Clofibrate does have effects on plasma fibrinogen," platelet adhesiveness,'2 and on the vascular wall,'3 and these may play some part in the prevelntion of atherosclerosis or arterial thrombosis.
There is still a real need for a completely satisfactory, multicentre study of the prevention of further infarction. Only after many more measurements have been made can the mode of action and usefulness of clofibrate be decided. For the moment its use remains empirical. The results at present available give general support to the current practice of prescribing clofibrate for patients with any degree of hyperlipidaemia, especially when there are symptoms of ischaemic heart disease. If the evidence in favour of a nonlipid-lowering mode of action emerges, clofibrate will become widely used for patients without lipid disturbance. But this cannot be recommended at the present time.
Physicians of the Newcastle upon Tyne Region, British Medical Journal,
The mortality rates for cancer of the cervix uteri have been declining in successive generations of women in England and Wales except for an apparent reversal of the downward trend in the group born between 1911 and 1924.1 It had occurred to G. B. Hill and A. M. Adelstein that these women would have been in adolescence and early womanhood during the years of the second world war, when sexual customs were changing and promiscuity, which is known to be associated with carcinoma of the cervix, was increasing. The extension of the study to some 18 other countries required that rates for carcinoma of the uterus be used because there were inadequate data for the cervix alone.2 Adelstein, Hill, and L. Maung2 found 11 countries where a similar rise in the death rate occurred at about the same time, each followed by a subsequent fall, though two countries, the U.S.A. and Japan, showed no changes in the downward trend over the birth period 1889-1929-that is, for women aged 40-80 in 1969. They believe that the only explanation for the sudden peak is the prevalence, especially during the second world war, of a venerally transmitted infectious agent such as Herpesvirus hominis type 2 (HSV-2).
If the virus is not the direct cause of this cancer, then the evidence for its association with the disease is either that
